Finally, in tumors with homologous recombination repair defects, PARP inhibitors are also capable of augmenting PD-1/PD-L1 inhibitors through enhancing tumor immunogenicity and cGAS/STING signaling activity [187,188]. Here, STING1 is linked to neoplasm.